Connect your AI

Cogent Biosciences, Inc. COGT Debt Repayments

Debt Repayments at other companies

Gilead SciencesGILD

——

Other financials

Income statement

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation

Market cap$5.9B+816%

Enterprise value$5.68B+951%

P/S749.8×—

Profitability

Operating margin-1,044.3%—

Net margin-950.4%—

FCF margin-184.7%—

Returns & leverage

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfDebt.

The official record: Cogent Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cogent Biosciences, Inc.'s debt repayments?: Cogent Biosciences, Inc. (COGT) reported debt repayments of $13.66M in Q4 2025.